Get the Stockscreener App
0.5973
0.64%
0.0038
Mustang Bio Inc stock is traded at $0.5973, with a volume of 6,023.
It is up +0.64% in the last 24 hours and down -4.92% over the past month.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
See More
Previous Close:
$0.5935
Open:
$0.5941
24h Volume:
6,023
Relative Volume:
0.06
Market Cap:
$4.55M
Revenue:
-
Net Income/Loss:
$-2.72M
P/E Ratio:
-1.2441
EPS:
-0.4801
Net Cash Flow:
$-4.88M
1W Performance:
+1.22%
1M Performance:
-4.92%
6M Performance:
-32.87%
1Y Performance:
-66.25%
1-Day Range:
$0.5941
$0.60
1-Week Range:
$0.5803
$0.6225
52-Week Range:
$0.525
$1.85
Mustang Bio Inc Stock (MBIO) Company Profile
Name
Mustang Bio Inc
Sector
Industry
Phone
(781) 652-4500
Address
95 SAWYER RD, WALTHAM, NY
Compare MBIO vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBIO
Mustang Bio Inc
|
0.60 | 4.50M | 0 | -2.72M | -4.88M | -0.4801 |
VRTX
Vertex Pharmaceuticals Inc
|
515.50 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.71 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
991.46 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.24 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.25 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Mustang Bio Inc Stock (MBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-21 | Initiated | BTIG Research | Buy |
| Oct-02-20 | Initiated | B. Riley FBR | Buy |
| Nov-20-19 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-19 | Initiated | H.C. Wainwright | Buy |
| Jun-21-19 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Initiated | Oppenheimer | Outperform |
View All
Mustang Bio Inc Stock (MBIO) Latest News
Mustang Bio Inc (MBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Segment Evaluation and Major Growth Areas in the Viral Vector Production (Research-Use) Market - openPR.com
Leading Companies Consolidating Their Presence in the Viral Vector Manufacturing Market - openPR.com
Mustang Bio Q2 net loss widens 41% to $1.07 million - Bitget
MUSTANG BIO, INC. Q2 2026: Net income $(1.07)M, EPS $(0.16) — 10-Q Summary - TradingView
MBIO: Net loss widened, cash reserves declined, and Nasdaq delisting risk remains amid ongoing R&D focus - TradingView
Mustang Bio, Inc. (NASDAQ: MBIO) posts $2.0M loss and faces Nasdaq bid-price warning - Stock Titan
Mustang Bio (MBIO) Holds $0.58 Support Zone as Gene Therapy Stock Ticks HigherBreakout Confirmation - dars.gov.et
Glioblastoma Pipeline 2026: FDA Approvals, Therapies, - openPR.com
Mustang Bio Inc (MBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mustang Bio, Inc. Revenue Breakdown – NASDAQ:MBIO - TradingView
Mustang Bio Inc (MBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mustang Bio Inc (MBIO) Cash Flow - TradingKey
MBIO|Mustang Bio Inc|Price:0.560|Chg%:-0.002 - TradingKey
TradingKey - TradingKey
Mustang Bio (MBIO) Slips Slightly as Stock Hovers Near Key Support ZoneCall Flow Alert - dars.gov.et
Frontier tech research, news & data - MLQ.ai
Car T Cell Therapy Market Set to Booming Growth 2026-2033 | Novartis AG, Gilead Sciences, Inc - EIN News
Mustang Bio stock trades lower as cash runway and trial update shape outlook - Ad-hoc-news.de
Mesa Royalty Trust (MTR) Declines 2.2% as Stock Nears Critical Support at $2.95Shakeout Pattern - po-news-eg.net
MSN Money - MSN
Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Significant EPS Miss Amidst Ongoing Operational ChallengesLow Estimate Range - dars.gov.et
Americore Resources Appoints Justin Hanka to Its Board of Directors - Moomoo
AstraZeneca’s Clinical Setback Casts Doubt on Premium Valuation Amid Pipeline ConcernsMargin Expansion Trends - po-news-eg.net
Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Deep Losses Overshadow Progress in CAR T PipelineGuidance Update - DonanımHaber
Mustang Bio (MBIO) Q1 2026 earnings summary - Quartr
Mustang Bio (MBIO) Proxy Filing Summary - Quartr
Mustang Bio (MBIO) Registration Filing Summary - Quartr
TDW Q1 2026 Earnings: Significant EPS Miss Despite Stock GainDebt Analysis Report - dars.gov.et
MBIO Should I Buy - Intellectia AI
MBIO Q4 2024 Earnings: Massive EPS Miss as Clinical-Stage Biotech Reports No RevenueEarnings Revision Report - dars.gov.et
MBIO Q4 2024 Earnings: Significant EPS Miss as Pre-Revenue Biotech Continues DevelopmentFinancial Summary - dars.gov.et
Enterprise value to EBIT forward of Mustang Bio, Inc. – NASDAQ:MBIO - TradingView
Enterprise value to EBITDA forward of Mustang Bio, Inc. – NASDAQ:MBIO - TradingView
Enterprise value to EBIT forward of Mustang Bio, Inc. – BOATS:MBIO - TradingView
Price to earnings forward of Mustang Bio, Inc. – NASDAQ:MBIO - TradingView
Price to book forward of Mustang Bio, Inc. – NASDAQ:MBIO - TradingView
Price to earnings forward of Mustang Bio, Inc. – BOATS:MBIO - TradingView
Enterprise value to revenue forward of Mustang Bio, Inc. – NASDAQ:MBIO - TradingView
Price to sales forward of Mustang Bio, Inc. – NASDAQ:MBIO - TradingView
Price to sales forward of Mustang Bio, Inc. – BOATS:MBIO - TradingView
Traders are paying attention to the gapping stocks in Friday's session. - ChartMill
Mustang Bio Inc (MBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Mustang Bio, Inc. Actuals & Estimates (NASDAQ:MBIO) - TradingView
MBIO Q4 2024 Earnings: Massive EPS Miss as Pre-Revenue Biotech Faces Cash Burn ChallengesGAAP Earnings Report - Bölüm Sonu Canavarı
Silver Tiger Metals Inc.'s (TSE:SLVR) Path To Profitability - simplywall.st
Mustang Bio Inc. (MBIO) Edges Higher Amid Tight Trading Range: Key Levels in FocusAAII Bullish - dars.gov.et
Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Significant EPS Miss Reflects Ongoing Clinical-Stage Challenges - dars.gov.et
MBIO Q4 2024 Earnings: Wider-than-Expected Loss Amid Clinical ProgressGuidance Revision Trend - dars.gov.et
Glioma Pipeline Insights Accelerates as 180+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com
EQR Q1 2026 Earnings: EPS Misses Estimates, Stock Edges LowerStrong Earnings Momentum - dars.gov.et
Mustang Bio Inc Stock (MBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mustang Bio Inc Stock (MBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chill Adam J. | Director |
Dec 30 '25 |
Sale |
0.95 |
4 |
4 |
375 |
| Jin David | Director |
Dec 30 '25 |
Buy |
0.96 |
247 |
238 |
286 |
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):